Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Purpose

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Condition

  • Prostatic Neoplasms

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Must have histologically or cytologically confirmed adenocarcinoma of the prostate - Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria

  • Prior treatment with an androgen receptor (AR) degrader - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP - Clinically significant venous thromboembolism within 3 months prior to the first dose of IP - Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Administration of CC-94676, CC1083611, and CC1083610
  • Drug: CC-94676
    Specified dose on specified days
    Other names:
    • BMS-986365
  • Drug: CC1083611
    Specified dose on specified days
    Other names:
    • BMS-986409
  • Drug: CC1083610
    Specified dose on specified days
    Other names:
    • BMS-986410

Recruiting Locations

Medstar Washington Hospital Center
Washington, District of Columbia 20010
Contact:
Suthee Rapisuwon, Site 122
216-773-2688

More Details

Status
Recruiting
Sponsor
Celgene

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com